We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+16.37%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$441M
AUM Growth
+$26.2M
Cap. Flow
+$45.7M
Cap. Flow %
10.38%
Top 10 Hldgs %
36.84%
Holding
138
New
52
Increased
12
Reduced
20
Closed
21

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$10.8M
2
INSM icon
Insmed
INSM
+$9.42M
3
BBIO icon
BridgeBio Pharma
BBIO
+$6.93M
4
APLS
Apellis Pharmaceuticals
APLS
+$5.77M
5
BCYC
Bicycle Therapeutics
BCYC
+$5.19M

Top Sells

Rank Stock Value
1
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$18.8M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$10.2M
3
CLDX icon
Celldex Therapeutics
CLDX
+$6.97M
4
BHVN icon
Biohaven
BHVN
+$6.93M
5
ETNB
89bio
ETNB
+$5.78M

Sector Composition

Rank Sector Weight
1 Healthcare 53.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KZR
51
DELISTED
Kezar Life Sciences
KZR
$2.63M 0.6%
84,160
+21,161
+34% +$1.22M
IMVT icon
52
CALL
Immunovant
IMVT
$7.93B
$2.49M 0.56%
160,300
+134,100
+512% +$2.33M
BTAI icon
53
BioXcel Therapeutics
BTAI
$24.9M
$2.48M 0.56%
8,313
-7,312
-47% -$3.12M
ACRS icon
54
Aclaris Therapeutics
ACRS
$726M
$2.43M 0.55%
+300,163
New +$3.81M
VTYX
55
DELISTED
Ventyx Biosciences
VTYX
$2.18M 0.49%
+65,000
New +$2.53M
ESPR
56
DELISTED
Esperion Therapeutics
ESPR
$2.16M 0.49%
1,355,605
-535,542
-28% -$2.76M
JSPR icon
57
Jasper Therapeutics
JSPR
$21M
$2.04M 0.46%
+112,629
New +$2.08M
CYTK icon
58
Cytokinetics
CYTK
$10.5B
$1.96M 0.44%
+55,666
New +$2.27M
AKRO
59
DELISTED
Akero Therapeutics
AKRO
$1.91M 0.43%
+50,000
New +$2.23M
MIST icon
60
Milestone Pharmaceuticals
MIST
$138M
$1.81M 0.41%
460,416
– –
MGNX icon
61
MacroGenics
MGNX
$235M
$1.79M 0.41%
+250,000
New +$1.51M
MORF
62
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$1.73M 0.39%
+45,873
New +$1.69M
CRBP icon
63
Corbus Pharmaceuticals
CRBP
$166M
$1.4M 0.32%
192,260
+179,021
+1,352% +$783K
ARKG icon
64
ARK Genomic Revolution ETF
ARKG
$1.57B
$1.4M 0.32%
46,462
– –
BTAI icon
65
CALL
BioXcel Therapeutics
BTAI
$24.9M
$1.33M 0.3%
+4,450
New +$1.9M
BLUE
66
DELISTED
bluebird bio
BLUE
$1.31M 0.3%
20,631
-20,000
-49% -$2.28M
BMEA icon
67
PUT
Biomea Fusion
BMEA
$84.6M
$1.24M 0.28%
+40,000
New +$497K
MRTX
68
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$1.23M 0.28%
33,100
-75,000
-69% -$3.37M
KPTI icon
69
Karyopharm Therapeutics
KPTI
$43.5M
$1.17M 0.26%
+20,000
New +$987K
SRPT icon
70
Sarepta Therapeutics
SRPT
$1.57B
$1.15M 0.26%
8,324
-20,000
-71% -$2.59M
ICPT
71
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$1.14M 0.26%
85,200
– –
ACAD icon
72
Acadia Pharmaceuticals
ACAD
$4.43B
$1.13M 0.26%
60,000
-265,000
-82% -$5.05M
KALV
73
DELISTED
KalVista Pharmaceuticals
KALV
$1.1M 0.25%
+140,000
New +$1.04M
DCTH icon
74
Delcath Systems
DCTH
$422M
$1.08M 0.24%
+360,569
New +$1.6M
OCUL icon
75
Ocular Therapeutix
OCUL
$1.79B
$1.05M 0.24%
200,000
– –
1 2
3
4 5

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q1 2023 Portfolio in Review

As of Q1 2023, Ikarian Capital held 138 positions worth $441M, up 6.3% from $415M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Ikarian Capital deployed $45.7M of net new capital in Q1 2023, opening 52 new positions and adding to 12 existing holdings. Its largest new stake was Merck: 100,000 shares worth $10.6M.

By sector, the portfolio is most concentrated in Healthcare at 53% of assets, down from 58% a quarter earlier.

On the sell side, the largest reduction was Prometheus Biosciences, Inc. Common Stock, an estimated $18.8M trimmed.

  • Ikarian Capital's largest Q1 2023 buy was Merck: 100,000 shares worth $10.6M.
  • Ikarian Capital added most to Altimmune in Q1 2023, an estimated $4.8M increase.
  • Ikarian Capital's biggest Q1 2023 reduction was Prometheus Biosciences, Inc. Common Stock, cutting an estimated $18.8M.
  • Ikarian Capital fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2023, selling an estimated $10.2M.
  • Ikarian Capital's ten largest holdings make up 37% of its $441M portfolio in Q1 2023.
  • Ikarian Capital opened 52 new positions and closed 21 in Q1 2023.
  • Ikarian Capital's portfolio value rose 6.3% quarter-over-quarter to $441M.

Based on Ikarian Capital's 13F filing for Q1 2023, filed 15 May 2023.